Terms: = Thyroid cancer AND HOXD11, ENSG00000128713, 3237
4 results:
1. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract] [Full Text] [Related]
2. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
[TBL] [Abstract] [Full Text] [Related]
3. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors.
Lamberts SW; Reubi JC; Krenning EP
Acta Oncol; 1993; 32(2):167-70. PubMed ID: 8391830
[TBL] [Abstract] [Full Text] [Related]
4. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract] [Full Text] [Related]
